Medilines Distributors Incorporated : Declaration of Cash Dividends
August 17, 2022 at 11:14 am IST
Share
SECURITIES AND EXCHANGE COMMISSIONSEC FORM 17-C
CURRENT REPORT UNDER SECTION 17
OF THE SECURITIES REGULATION CODE
AND SRC RULE 17.2(c) THEREUNDER
1. Date of Report (Date of earliest event reported) Aug 17, 20222. SEC Identification Number CS2002510643. BIR Tax Identification No. 2190756144. Exact name of issuer as specified in its charter MEDILINES DISTRIBUTORS INCORPORATED5. Province, country or other jurisdiction of incorporation Metro Manila, Philippines6. Industry Classification Code(SEC Use Only) 7. Address of principal office 3rd Floor, Vitamall Hub, C.V. Starr Ave., Pamplona Dos, Las Pinas CityPostal Code17408. Issuer's telephone number, including area code +6377471076/+63851920129. Former name or former address, if changed since last report N/A10. Securities registered pursuant to Sections 8 and 12 of the SRC or Sections 4 and 8 of the RSA
Title of Each Class
Number of Shares of Common Stock Outstanding and Amount of Debt Outstanding
Common
2,750,000,800
11. Indicate the item numbers reported herein Item 9
The Exchange does not warrant and holds no responsibility for the veracity of the facts and representations contained in all corporate disclosures, including financial reports. All data contained herein are prepared and submitted by the disclosing party to the Exchange, and are disseminated solely for purposes of information. Any questions on the data contained herein should be addressed directly to the Corporate Information Officer of the disclosing party.
Medilines Distributors IncorporatedMEDIC
PSE Disclosure Form 6-1 - Declaration of Cash Dividends References: SRC Rule 17 (SEC Form 17-C) and
Sections 6 and 4.4 of the Revised Disclosure Rules
Subject of the Disclosure
Declaration of Cash Dividends for 2Q2022
Background/Description of the Disclosure
Please be informed that the Board of Directors, in their Special Meeting on August 17, 2022, has approved the declaration of cash dividends equivalent to 5% of the Company's Net Income After Tax as of December 31, 2021, equivalent to Php0.0030842082 per share or a total amount of Php8,481,575 in favor of all its stockholders of record date as of September 1, 2022, payable on September 22, 2022.
Type of Securities
Common
Preferred-
Others-
Cash Dividend
Date of Approval by Board of Directors
Aug 17, 2022
Other Relevant Regulatory Agency, if applicable
N/A
Date of Approval by Relevant Regulatory Agency, if applicable
N/A
Type (Regular or Special)
Special
Amount of Cash Dividend Per Share
Php0.0030842082
Record Date
Sep 1, 2022
Payment Date
Sep 22, 2022
Source of Dividend Payment
Net Income After Tax as of December 31, 2021
Other Relevant Information
Please see attached SEC Form 17-C
Filed on behalf by:
Name
Luis Melquiades Garcia III
Designation
Investor Relations and Compliance Officer
Attachments
Original Link
Original Document
Permalink
Disclaimer
Medilines Distributors Inc. published this content on 17 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 August 2022 05:43:08 UTC.
Medilines Distributors, Inc. is a Philippines-based distributor of critical medical equipment to public and private healthcare facilities across the Philippines. Its products such as linear accelerators for cancer treatment, dialysis machines for treatment of kidney diseases, and imaging machines such as computerized tomography (CT), x-rays, and magnetic resonance imaging (MRI). It is focused on three core categories: diagnostics imaging, dialysis, and cancer therapy. It manufactures equipment in advanced therapy, which includes C-Arm, Cathlab, Robotics. Its Molecular Imaging, which includes PET CT and SPECT CT. Its renal care includes dialysis machines, consumables, and accessories. Its radiation therapy includes Varian Halcyon, and Varian True Beam. Its diagnostic imaging products include Multix Impact, Elara Max, Polymobil Plus, and Magnetom Skyra. Its brands include Siemens Healthineers for diagnostic imaging, B. Braun for dialysis, and Varian for cancer therapy.